Lakefront Biotherapeutics (LKFT) Accounts Payables (2013 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Accounts Payables for 13 consecutive years, with $112.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables fell 36.91% year-over-year to $112.1 million; the TTM figure through Mar 2026 stood at $112.1 million (down 36.91% YoY), while the FY2025 annual figure was $121.8 million, up 15.29% from the prior year.
• Accounts Payables declined to $112.1 million in Q1 2026 per LKFT's latest filing, from $121.8 million in the prior quarter.
• Across five years, Accounts Payables topped out at $177.7 million in Q1 2025 and bottomed at $105.7 million in Q4 2024.
• Historically, Accounts Payables has averaged $139.9 million across 5 years, with a median of $145.5 million in 2023.
• Annual changes were most pronounced in 2025 — Accounts Payables climbed 15.29% — and 2026, when it sank 36.91%.
• Lakefront Biotherapeutics' Accounts Payables stood at $151.7 million in 2022, then dropped by 4.1% to $145.5 million in 2023, then retreated by 27.37% to $105.7 million in 2024, then climbed by 15.29% to $121.8 million in 2025, then fell by 7.96% to $112.1 million in 2026.
• Business Quant data shows LKFT's Accounts Payables at $112.1 million in Q1 2026, $121.8 million in Q4 2025, and $117.6 million in Q3 2025.